Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 81.20
-4.40 (-5.14%)
At close: Mar 27, 2026
TPE:6919 Revenue
In the year 2025, Caliway Biopharmaceuticals had annual revenue of 38.04M TWD, down -14.40%. Caliway Biopharmaceuticals had revenue of 12.41M in the quarter ending December 31, 2025, with 32.54% growth.
Revenue
38.04M
Revenue Growth
-14.40%
P/S Ratio
3,315.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
126.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.04M | -6.40M | -14.40% |
| Dec 31, 2024 | 44.43M | 5.50M | 14.13% |
| Dec 31, 2023 | 38.93M | 26.11M | 203.68% |
| Dec 31, 2022 | 12.82M | 481.00K | 3.90% |
| Dec 31, 2021 | 12.34M | 1.99M | 19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.03B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| Oneness Biotech | 129.12M |
| Polaris Group | 40.60M |
| Lumosa Therapeutics | 35.83M |